183500-94-9

Basic information

• Product Name: 1-(3-CHLOROPHENYL)PIPERAZIN-2-ONE HYDROCHLORIDE
• Synonyms: 1-(3-CHLOROPHENYL)PIPERAZIN-2-ONE HYDROCHLORIDE
• CAS NO: 183500-94-9
• Molecular Formula: C10H12Cl2N2O
• Molecular Weight: 247.12108
• Mol File: 183500-94-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 443.9 °C at 760 mmHg
• Flash Point: 222.3 °C
• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(3-CHLOROPHENYL)PIPERAZIN-2-ONE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-CHLOROPHENYL)PIPERAZIN-2-ONE HYDROCHLORIDE(183500-94-9)
• EPA Substance Registry System: 1-(3-CHLOROPHENYL)PIPERAZIN-2-ONE HYDROCHLORIDE(183500-94-9)

Safety Data

• Hazardous Substances Data: 183500-94-9(Hazardous Substances Data)

Usage

General Description

1-(3-Chlorophenyl)piperazin-2-one hydrochloride is a chemical compound that belongs to the piperazine class of molecules. It is a white crystalline powder that is soluble in water and ethanol. 1-(3-Chlorophenyl)piperazin-2-one hydrochloride has been studied for its potential as a psychoactive drug and has been found to have some activity on the central nervous system. It has been used in research settings to study its effects on neurotransmitter systems and to explore its potential as a treatment for various conditions such as anxiety, depression, and schizophrenia. However, its use as a psychoactive drug is not approved for medical or recreational use and it is considered a controlled substance in some countries.

Upstream product

• 183500-69-8 4-(tert-butoxycarbonyl)-1-(3-chlorophenyl)-2-piperazinone 
• 108-42-9 3-chloro-aniline 
• 2564-05-8 2-chloro-N-(3-chlorophenyl)acetamide 
• 215649-70-0 N¹-(3-chlorophenyl)-N²-(2-hydroxyethyl)glycinamide 

Relevant articles and documents

Synthesis and cytotoxicity evaluation of some novel 1-(3-Chlorophenyl) piperazin-2-one derivatives bearing imidazole bioisosteres

A series of substituted 3-chlorophenylpiperazinone derivatives were synthesised using L-778123 (an imidazole-containing FTase inhibitor) as a model by bioisosteric replacement of the imidazole ring. The final compounds were evaluated against two human cancer cell lines including A549 (lung cancer) and HT-29 (colon cancer) by MTT assay. The results showed that substitution of imidazole ring with 1-amidinourea, semicarbazide, and thiobiuret led to improvement of cytotoxic activity against both cell lines.

Preparation of a clinically investigated ras farnesyl transferase inhibitor

The synthesis of ras farnesyl-protein transferase inhibitor 1 is described on a multi-kilogram scale. Retrosynthetic analysis reveals chloromethylimidazole 2 and a piperazinone 3 as viable precursors. The 1,5-disubstituted imidazole system was regioselectively assembled via an improved Marckwald imidazole synthesis. A new imidazole dethionation procedure has been developed to convert the Marckwald mercaptoimidazole product to the desired imidazole. This methodology was found to be tolerant of a variety of functional groups providing good to excellent yields of 1,5-disubstituted imidazoles. A new Mitsunobu cyclization strategy was developed to prepare the arylpiperazinone fragment 3.

Sustained release drug dispersion delivery device

The present invention is related to a drug delivery device, that is pH insensitive, for the sustained in situ production and release of a dispersion, in an environment of use, which comprises a) a compressed core prepared from an admixture comprising i) a